Evidence map›Paper›PMID 34105277›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021

Multi-Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation.

Liting Wang, Qing Shen, Hongze Liao, Hao Fu, Qi Wang, Jian Yu, Wei Zhang, Chuanrong Chen, Yang Dong, Xupeng Yang and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. A review of 3D bioprinting for organoids.Medical review (2021) · 2025
    Review
  5. Review
  6. Article
  7. Multi-stage mechanisms of tumor metastasis and therapeutic strategies.Signal transduction and targeted therapy · 2024
    Review
  8. Article
  9. Peptidomimetics in cancer targeting.Molecular medicine (Cambridge, Mass.) · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Liting WangState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Qing ShenState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Hongze LiaoResearch Center for Marine Drugs, State Key Laboratory of Oncogenes and Related Genes, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.ORCID 0000-0003-1340-6811
Hao FuState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Qi WangShanghai Key Laboratory of Functional Materials Chemistry, School of Chemistry and Molecular Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Jian YuState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Wei ZhangState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Chuanrong ChenState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Yang DongState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Xupeng YangState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Qianqian GuoState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Jiali ZhangState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.
Jian ZhangDepartment of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Wei ZhangResearch Center for Marine Drugs, State Key Laboratory of Oncogenes and Related Genes, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Houwen LinState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.ORCID 0000-0002-7097-0876
Yourong DuanState Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, School of Biomedical Engineering, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, China.ORCID 0000-0002-3781-7845
Shanghai Jiao Tong University · CNEast China University of Science and Technology · CN

Funding

Innovative Research Team of High-Level Local Universities in Shanghai SSMU-ZLCX20180702National Natural Science Foundation of China 21807071National Natural Science Foundation of China 41729002National Natural Science Foundation of China 81903499National Natural Science Foundation of China 81972886
6 · The paper itself

Abstract

The binding of amyloid precursor protein (APP) expressed on tumor cells to death receptor 6 (DR6) could initiate the necroptosis pathway, which leads to necroptotic cell death of vascular endothelial cells (ECs) and results in tumor cells (TCs) extravasation and metastasis. This study reports the first inhibitor of DR6/APP interaction as a novel class of anti-hematogenous metastatic agent. By rationally utilizing three combined strategies including selection based on phage display library, d-retro-inverso modification, and multiple conjugation of screened peptidomimetic with 4-arm PEG, the polymer-peptidomimetic conjugate PEG-tAHP-DRI (tetra-(D-retro-inverso isomer of AHP-12) substitued 4-arm PEG

Indexed as

Amyloid beta-Protein PrecursorAnimalsCell CommunicationDisease Models, AnimalEndothelial CellsHematologic NeoplasmsHumansLigandsMelanoma, ExperimentalMiceNeoplasm MetastasisPeptidomimeticsReceptors, Tumor Necrosis FactorTransendothelial and Transepithelial MigrationAmyloid beta-Protein PrecursorLigandsPeptidomimeticsReceptors, Tumor Necrosis FactorTNFRSF21 protein, humananti-hematogenous metastatic activitiespolymer-peptidomimetic conjugatesprotein-protein interactionsstructure-based drug design

Identifiers

PMID34105277
PMCPMC8188212
OpenAlexW3212775964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.